Syndax Pharmaceuticals (NASDAQ: SNDX) net income
Syndax Pharmaceuticals reported a net loss of $285.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $318.8m. Earnings per share were −$3.29.
Syndax Pharmaceuticals's best year of the last 10 was fiscal 2021. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$285.4m | — | −165.6% | −$3.29 |
| 2024 | −$318.8m | — | −1,346.1% | −$3.72 |
| 2023 | −$209.4m | — | — | −$2.98 |
| 2022 | −$149.3m | −699.1% | — | −$2.46 |
| 2021 | $24.9m | — | 17.8% | $0.48 |
| 2020 | −$73.2m | — | −4,822.5% | −$1.87 |
| 2019 | −$56.0m | — | −3,694.6% | −$1.84 |
| 2018 | −$74.0m | — | −4,875.5% | — |
| 2017 | −$60.8m | — | −2,884.3% | — |
| 2016 | −$44.5m | — | −3,645.2% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Syndax Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Syndax Pharmaceuticals ranks 444th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Syndax Pharmaceuticals, −165.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 442nd | Kura Oncology | −$278.7m | −412.9% |
| 443rd | Claritev | −$284.3m | −29.4% |
| 444th | Syndax Pharmaceuticals | −$285.4m | −165.6% |
| 445th | Madrigal Pharmaceuticals | −$288.3m | −30.1% |
| 446th | Minerva Neurosciences | −$293.4m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Syndax Pharmaceuticals
- How much did Syndax Pharmaceuticals earn in fiscal 2025?
- Syndax Pharmaceuticals reported a net loss of $285.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $318.8m.
- What are the earnings per share of Syndax Pharmaceuticals?
- They were −$3.29 in fiscal 2025, compared with −$3.72 in fiscal 2024.
- What was the most profitable year for Syndax Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2021, with $24.9m.
- Where does Syndax Pharmaceuticals rank in its sector by net income?
- It ranks 444th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Syndax Pharmaceuticals come from?
- From the annual report (Form 10-K) that Syndax Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Syndax Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Syndax Pharmaceuticals: the Syndax Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.